INmune Bio Inc. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled "XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial," has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.